Chimeric Therapeutics Ltd. (AU:CHM) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Chimeric Therapeutics has announced a collaboration with Achieve Clinics to propel the accessibility of its innovative CHM CDH17 cell therapy for cancer patients. By utilizing Achieve’s PRO-Aph™ proactive apheresis, the partnership aims to streamline the development of Chimeric’s cell therapy and improve patient enrollment by collecting and storing patients’ cells early in treatment. This strategic move could potentially expedite the availability of Chimeric’s cell therapy to more patients suffering from gastrointestinal and neuroendocrine tumors.
For further insights into AU:CHM stock, check out TipRanks’ Stock Analysis page.